pharmaceuticals

pharmaceuticals Articles

Shares of Lexicon Pharmaceuticals saw a hand gain early on Friday after the company reported top-line results from its late-stage trial in type-1 diabetes.
Inovio Pharmaceuticals shares posted a solid gain on Thursday after the company announced that it was beginning its late-stage trial of its treatment for cervical dysplasia caused by human...
Valeant Pharmaceuticals shares made a solid gain on Thursday after the company announced the sale of its iNova Pharmaceutical business.
SciClone Pharmaceuticals saw its shares make a solid gain early on Thursday after it was announced that the company entered into a definitive agreement to be acquired by a consortium of companies.
Shares of Inovio Pharmaceuticals saw a handy gain early on Wednesday after the company gave an update on its Zika virus study.
Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO). Unfortunately, the move was to the downside.
Athenex expects to price 6 million shares in the range of $11 to $13 apiece for an initial public offering is valued up to more than $89 million.
Aileron Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care sector is on the move.
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
Mersana Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Just ahead of the 2017 annual meeting of the American Society of Clinical Oncology, a new report shows that more than 240 immuno-oncology medicines and vaccines are currently in development.
Here are seven speculative biotech and biohealth stocks where analysts gave huge upside calls during the month of May 2017.
Protagonist Therapeutics Inc. (NASDAQ: PTGX) saw its shares move up so much on May 30 that some investors probably just assumed this was a takeover or that the company had major news shaking the...
Protagonist Therapeutics saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech.